| International Session（Symposium）2(JSGE・JGES) |
| Thu. November 21st 14:00 - 16:30 Room 11: Portopia Hotel South Wing Topaz |
| Small bowel endoscopic healing of Crohn’s disease treated with anti-TNF antibodies | |||
| Kento Takenaka1, Kazuo Ohtsuka1, Mamoru Watanabe1 | |||
| 1Tokyo Medical and Dental University | |||
|
|||
|
|||
| Background: Objective assessment of Crohn`s disease (CD) in patients treated with anti-tumor necrosis factor (anti-TNF) antibodies is crucial. Endoscopic healing (EH) has a strong predictive value for outcome, but small bowel (SB)-EH has been much less studied. Methods: This is post hoc analysis on prospectively collected data from patients with CD who received induction and then maintenance therapy with anti-TNF antibodies therapy from January 2013 to September 2017. We compared balloon-assisted enteroscopic findings both before treatment and during maintenance therapy. Results: Overall, 45 patients with ileal (L1) and 65 with ileocolonic (L3) CD were enrolled into this study. During maintenance, SB-EH was achieved in 12 of 45 (27%) patients with L1 disease. In L3 disease, SB-EH was achieved in 27 of 63 (43%) and colonic EH in 30 of 39 (77%). Among those with L3 disease, the rate of SB-EH was significantly lower than that of colonic EH (P < 0.01). Among all patients, failure to achieve SB-EH was significantly associated with delayed treatment (over 2 years after diagnosis), B2 or B3 behavior, lack of treatment with immunomodulators, and patients not being treatment naïve (P = 0.02, P = 0.02, P = 0.03, P < 0.01, respectively). Conclusion: As assessed endoscopically, SB inflammation was more difficult to treat with anti-TNF antibodies than colonic inflammation. |
|||
|
Index Term 1: crohn's disease Index Term 2: endoscopic healing |
|||
| Page Top | |||